Searched for
ALBUTEROL MDI
Cipla Q2 Results: Net profit grows 4% YoY to Rs 1,351 crore; revenue rises 8%Cipla Q2 Results: Cipla reported a 4% YoY growth in net profit to Rs 1,351 crore and an 8% rise in revenue to Rs 7,589 crore. The company s...- Lupin inks pact to acquire two inhalation brands from Sunovion for USD 75 mnThe acquisition of these two brands will expand the company's inhalation product portfolio in the US and strengthen its presence in the res...
- Pharma’s perennial underperformer gets a shot in the arm. Can it deliver?The stock has gained 64 per cent from March lows and 27 per cent year to date, but still 54 per cent down from its all-time high of Rs 2,12...
- Lupin gets US health regulator's approval for asthmatic symptoms prevention drugThe approved product is a generic version of ProAir HFA of Teva Branded Pharmaceutical Products R&D, Inc. In a regulatory filing, Lupin sai...
- A big opportunity is beginning to unlock for us in the US: Cipla'Inhaler opportunity can add to Cipla’s position in lung medicines.'
- Cipla to raise Rs 3,000 crore, Q4 net misses Street view: Key takeawaysIt had posted a net profit of Rs 357.68 crore in the same quarter a year ago.
- Buy Cipla, target price Rs 522: Emkay GlobalCipla has received approval for generic proventil MDI (Albuterol Sulphate 90mcg/inhalation). This can lead to 3-4 per cent EPS accretion to...
- Cipla gets final approval from USFDA for Albuterol Sulfate Inhalation AerosolIn a regulatory filing the company said "it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfa...
Load More